A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment
A PhaseⅠStudy of Apatinib Mesylate (YN968D1) 1,000mg in Patients With Unresectable Locally Advanced or Metastatic Gastric Cancer Failed to Standard Therapy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Songpa-gu
-
Seoul, Songpa-gu, Korea, Republic of
- Asan Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 19 years of age or older
- Subjects with histologically confirmed unresectable locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction
- Failure or noncompliance of existing standard treatment without alternative treatment
- Measurable disease measured by proper image examination defined by RECIST 1.1
- Life expectancy ≥ 3 months
- Subject must be suitable for oral administration of study medication
- Subject who can submit a written consent form before participating in the test
- Adequate bone marrow, renal, and liver function
- Electrocorticography(ECOG) performance status ≤ 2
- Ability and willingness to comply with the study protocol for the duration of the study
Exclusion Criteria:
- Pregnant or lactating women
- Therapy with clinically significant systemic anticoagulant or antithrombotic agents within 7 days prior to first scheduled dose of YN968D1
- Hemoptysis within 3 months prior to first scheduled dose of YN968D1
- Cytotoxic chemotherapy, immunotherapy, radiotherapy or other targeted therapies within 4 weeks (6 weeks in cases of mitomycin C, nitrosourea, lomustine) prior to first scheduled dose of YN968D1
- Surgery or biopsy within 28 days prior to first scheduled dose of YN968D1
- Minor surgery within 7 days prior to first scheduled dose of YN968D1
- Patients who have experience using YN968D1 before
- Concomitant treatment with strong inhibitors or inducers of CYP3A4, CYP2C9 and CYP2C19
- Known history of human immunodeficiency virus infection (HIV)
- Medical history of other cancers (including blood cancer) in the 5 years
- Radiology therapy to target lesion within 28 days, or diagnosis of other cancer within 14 days prior to first scheduled dose of YN968D1
- History of bleeding diathesis or bleeding within 14 days prior to enrollment
- Medical history of clinically significant thrombosis (bleeding or clotting disorder) within the past 3-months
- History of non-malignant GI bleeding, gastric stress ulcerations, or peptic ulcer disease within the past 3-months
- History of idiopathic or hereditary angioedema, sickle cell or any hemolytic anemia
- History of uncontrolled hypertension that in the opinion of the investigator
- Complete Left bundle branch block (LBBB) or bifascicular (RBBB and left anterior or posterior hemi-block)
- Clinically significant S-T segment or T wave abnormality
- Abnormal atrial fibrillation
- History of ECOG or left ventricular ejection fraction (LVEF) abnormality during last 3 months in the opinion of the investigator
- Myocardial infarction or unstable angina pectoris within 6 months prior to starting study medication
- Congestive heart failure (New York Heart Association class III-IV)
- History of other significant cardiovascular disease or vascular disease within the last 6 months
- History of clinically significant glomerulonephritis, biopsy proven tubulointerstitial nephritis, crystal nephropathy, or other renal insufficiencies Treatment with an investigational agent within the longest time frame of either 5 half-lives or 30 days of initiating study drug
- Half-life of other investigator drug is not passed over fivefold or 30 days prior to clinical trial
- Known recreational substance use or psychiatric illness that, in the opinion of the Investigator, may affect compliance with scheduled visits
- Known hypersensitivity to YN968D1 or components of the formulation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Apatinib mesylate
|
1,000mg Apatinib mesylate p.o. qd
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dose-limiting toxicities (DLTs) of Apatinib mesylate in patients with unresectable locally advanced or metastatic gastric cancer
Time Frame: First 28 days of dosing
|
Graded and described using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v 4.03
|
First 28 days of dosing
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of Adverse events (AEs), Serious AEs (SAEs), clinical laboratory abnormalities, and ECG abnormalities
Time Frame: From date of registration to time of first progressive disease(PD) or death, an average of 1 year
|
Incidence and severity of treatment-related adverse events reported and their relationship to Apatinib mesylate will be assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.3)
|
From date of registration to time of first progressive disease(PD) or death, an average of 1 year
|
|
Duration of Response(Stable disease, partial response or Complete response)
Time Frame: From date of registration to time of first progressive disease(PD) or death, an average of 1 year
|
Tumor response and progression will be evaluated using RECIST v 1.1.
|
From date of registration to time of first progressive disease(PD) or death, an average of 1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Yoon-Koo Kang, PhD, Seoul ASAN Medical Center
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- BK-AM-GC102
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.